Lonza and Vertex Sign a Commercial Supply Agreement for Casgevy
Lonza and Vertex Pharmaceuticals recently announced a commercial supply agreement for casgevy (exagamglogene autotemcel).
Vertex Pharmaceuticals
Vertex to Acquire Alpine Immune Sciences for $4.9 Billion
US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
RoslinCT to Join Manufacturing Network for CRISPR-Based Therapy
UK’s RoslinCT, a cell and gene therapy contract development and manufacturing organization, will be part of the Vertex Pharmaceuticals global network producing the CRISPR-based therapy exa-cel, which will be used for treatment of sickle cell disease and transfusion-dependent beta thalassemia.
Lonza, Vertex Break Ground on New US Cell Therapy Plant
Last week, Lonza and Vertex Pharmaceuticals broke ground on a new US facility in Portsmouth, New Hampshire, to manufacture cell therapies for diabetes.
Vertex Buys ViaCyte for $320 Million
US-based Vertex Pharmaceuticals has agreed to pay $320 million in cash to acquire ViaCyte, a compatriot private cellular therapy company specializing in a treatment for type-1 diabetes (T1D). The transaction is expected to close later this year.
